Figure 5.

Effect of panobinostat and/or ponatinib on the expression of BCR‐ABL, phospho‐BCR‐ABL, and downstream signaling molecules in CML cell lines. All cell lines were treated for 24 h with panobinostat, ponatinib, or their combination at the indicated concentrations followed by Western blotting of BCR‐ABL expression (a). (b–e) (1) Western blotting of BCR‐ABL, STAT5, AKT, and ERK1/2 proteins (top) or their phosphorylated (p‐) forms (bottom). β‐Actin was assayed as a loading control. Band intensity was determined using densitometry and is indicated below each band. (b–e) (2) The combination of ponatinib with panobinostat at the indicated concentrations inhibited p‐BCR‐ABL expression more strongly than the sum of each agent alone.